Chemistry:Solbinsiran
From HandWiki
Short description: Small interfering RNA therapy
| Clinical data | |
|---|---|
| Other names | LY3561774; LY-3561774 |
| Legal status | |
| Legal status |
|
| Identifiers | |
| CAS Number | |
| UNII | |
Solbinsiran is a GalNAc conjugated small interfering RNA therapy that targets angiopoietin-like 3. It is developed by Eli Lilly and Company to reduce the level of apolipoprotein B and reduce the risk of cardiovascular disease.[1][2][3]
References
- ↑ Dudek, Hank; Abrams, Marc; Saxena, Utsav; Turanov, Anton; Brown, Bob; Ruotolo, Giacomo; Michael, Laura (2023-11-07). "Abstract 12705: Identification and Characterization of Solbinsiran, a GalNAc Conjugated siRNA Targeting Angiopoietin-Like 3". Circulation (Hagerstown, MD: Lippincott Williams & Wilkins) 148. doi:10.1161/circ.148.suppl_1.12705. https://www.ahajournals.org/doi/abs/10.1161/circ.148.suppl_1.12705. Retrieved 2023-11-24.
- ↑ Biessen, Erik A.L.; Van Berkel, Theo J.C. (December 2021). "N-Acetyl Galactosamine Targeting: Paving the Way for Clinical Application of Nucleotide Medicines in Cardiovascular Diseases". Arteriosclerosis, Thrombosis, and Vascular Biology 41 (12): 2855–2865. doi:10.1161/ATVBAHA.121.316290. PMID 34645280.
- ↑ Carugo, S.; Sirtori, C. R.; Gelpi, G.; Corsini, A.; Tokgozoglu, L.; Ruscica, M. (November 2023). "Updates in Small Interfering RNA for the Treatment of Dyslipidemias". Current Atherosclerosis Reports 25 (11): 805–817. doi:10.1007/s11883-023-01156-5. PMID 37792132.
 |  |
